LENZ Therapeutics Inc
LENZ
View Detailed Chart
27.930USD
-1.790-6.02%
Close 11/03, 16:00（ET）Quotes delayed by 15 min
796.01MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-6.02%
5 Days
-10.74%
1 Month
-42.70%
6 Months
-5.39%
Year to Date
-3.26%
1 Year
0.00%
View Detailed Chart
TradingKey Stock Score of LENZ Therapeutics Inc
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
LENZ Therapeutics Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Strong Buy
Current Rating
53.429
Target Price
+79.77%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
LENZ Therapeutics Inc Highlights
StrengthsRisks
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Undervalued
The company’s latest PE is -19.24, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 30.36M shares, increasing 3.24% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 14.61K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.11.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
LENZ Therapeutics Inc Info
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Ticker SymbolLENZ
CompanyLENZ Therapeutics Inc
CEOMr. Evert (Eef) Schimmelpennink
Website
Related Instruments
-0.49%
-0.66%
0.00%
-1.54%
+1.02%
-3.18%
-2.91%
-0.15%
+3.16%
-1.18%
+0.08%
-0.22%
-0.57%
-0.74%
0.00%
-0.61%
-0.11%
+0.03%
+1.08%
-9.33%Popular Symbols
